

DAFTAR PUSTAKA

- 1 Rasco DW, Yan J, Xie Y, Dowell JE, Gerber DE. Looking beyond surveillance, epidemiology, and end results: Patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population. *J Thorac Oncol* 2010; 5: 1529–35.
- 2 Yuliandra Y, Nasif H, Ermayanti S, Sulistyowati L, Juwita DA. Hematologic Toxicities of Chemotherapy in Lung Cancer Patients: A Retrospective Study in Dr. M. Djamil Hospital Padang, Indonesia. *Indones J Pharm* 2019; 8: 129–40.
- 3 Singh N, Aggarwal AN, Behera D, Jindal SK. Intercycle delays during chemotherapy of non-small cell lung cancer in a health care resource-constrained setting and their effect on overall survival. *J Thorac Oncol* 2010; 5: 236–9.
- 4 Wonders KY, Schmitz K, Harness J. Dose Delays, Dose Reductions, and Relative Total Dose Intensity in Patients With Advanced Cancer Who Exercised During Neoadjuvant Chemotherapy Treatment. *Integr Cancer Ther* 2023; 22: 1–10.
- 5 Crawford J, Denduluri N, Patt D, Jiao X, Morrow PK, Garcia J *et al.* Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer. *Support Care Cancer* 2020; 28: 925–32.
- 6 Jassem J, de Marinis F, Giaccone G, Vergnenegre A, Barrios CH, Morise M *et al.* Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC. *JTO* 2021; 16: 1872–82.
- 7 Hayashi H, Okamoto I, Morita S, Taguri M, Nakagawa K. Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer. *Ann Oncol* 2012; 23: 1537–41.
- 8 Mayasari E. SE. *Perbandingan efikasi dan toksisitas hematologi kemoterapi lini I kanker paru karsinoma bukan sel kecil (kpkbsk) jenis karsinoma sel skuamosa (kss) dengan adenokarsinoma egfr wild type di rsup persahabatan = The comparison of efficacy and hematological tox.* 2018.
- 9 Matsumoto K, Tamiya A, Matsuda Y, Taniguchi Y, Atagi S, Kawachi H *et al.* Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: A multicenter retrospective study. *Transl Lung Cancer Res* 2021; 10: 1642–52.
- 10 Malhotra V, Perry MC. Classical chemotherapy: mechanisms, toxicities and the therapeutic window. *Cancer Biol Ther* 2003; 2: 1–4.
- 11 E S. Kemoterapi untuk Kanker Paru. In: A J (ed). *Pengobatan Kanker Paru.* Departemen Pulmonologi dan Kedokteran Respirasi FK UI: Jakarta, 2019, pp 39–49.

- 12 Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK *et al.* Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. *Genes Dis* 2023; 10: 1367–1401.
- 13 Brown DL. Cellular Mechanisms of Chemotherapy. In: Gullatte MM, Schwartz R, Spinks R WD (ed). *Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook*. ONS: United States of America, 2015, pp 1–23.
- 14 Asmis TR, Ding K, Seymour L, Shepherd FA, Leighl NB, Winton TL *et al.* Age and comorbidity as independent prognostic factors in the treatment of non-smallcell lung cancer: A review of National Cancer Institute of Canada Clinical Trials Group Trials. *J Clin Oncol* 2008; 26: 54–9.
- 15 Florez N, Kiel L, Riano I, Patel S, DeCarli K, Dhawan N *et al.* Lung Cancer in Women: The Past, Present, and Future. *Clin Lung Cancer* 2023; 25: 1–8.
- 16 May L, Shows K, Nana-Sinkam P, Li H, Landry JW. Sex Differences in Lung Cancer. *Cancers (Basel)* 2023; 15: 1–20.
- 17 Xing PY, Li JL, Wang Y, Hao XZ, Wang B, Yang L *et al.* Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced non-small-cell lung cancer. *Chin J Cancer Res* 2013; 25: 200–5.
- 18 Mellemegaard A, Lüchtenborg M, Iachina M, Jakobsen E, Green A, Krasnik M *et al.* Role of comorbidity on survival after radiotherapy and chemotherapy for nonsurgically treated lung cancer. *J Thorac Oncol* 2015; 10: 272–9.
- 19 Tsao AS, Liu D, Lee JJ, Spitz M, Hong WK. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. *Cancer* 2006; 106: 2428–36.
- 20 Langer CJ, Li S, Schiller J, Tester W, Rapoport BL, Johnson DH. Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599. *J Clin Oncol* 2007; 25: 418–23.
- 21 Syahrudin E, Marlina N HA. Efikasi dan toksisitas rejimen sisplatin + etoposid untuk kemoterapi kanker paru karsinoma bukan sel kecil (KPKBSK) stage lanjut. *Respir Indon* 2012; 32: 2482–91.
- 22 Wu Y, Aravind S, Nalysnyk L, Ranganathan G. Dose Delay Amongst Cancer Patients Undergoing Chemotherapy. *Blood* 2008; 112: 4698–9.
- 23 Szejniuk WM, Cekala M, Bøgsted M, Meristoudis C, McCulloch T, Falkmer UG *et al.* Adjuvant platinum-based chemotherapy in non-small cell lung cancer: The role of relative dose-intensity and treatment delay. *Cancer Treat Res Commun* 2021; 27: 1–6.
- 24 Tabassum S, Rosli NB, Binti Mazalan MSA. Mathematical Modeling of

- Cancer Growth Process: A Review. *J Phys Conf Ser* 2019; 1366: 1–5.
- 25 Traina TA, Dugan U, Higgins B, Kolinsky K, Theodoulou M, Hudis CA *et al.* Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling. *Breast Dis* 2010; 31: 7–18.
- 26 Pulvers K, Scheuermann TS, Romero DR, Basora B, Luo X, Ahluwalia JS. Classifying a smoker scale in adult daily and nondaily smokers. *Nicotine Tob Res* 2014; 16: 591–9.
- 27 Crooks, V, Waller S *et al.* The use of Karnofsky Performance Scale in Determining Outcomes and risk in Geriatric Outpatients. *J Gerontol.* 1991; : 139–144.
- 28 Sembiring R., Hidajat H., Jusuf A. JS. Klasifikasi Histologi Kanker Paru. In: A. J (ed). *Dasar-dasar Diagnosis Kanker Paru.* UI-Press, 2017, pp 89–98.
- 29 Syahrudin E, Zaini J, Soehardiman D, Anwidyarningsih W, Icksan AG, Mety SH *et al.* *Pedoman Penstagingan dan Pengevaluasian Hasil Terapi di Indonesia.* Perhimpunan Dokter Paru Indonesia: Jakarta, 2019.
- 30 Jusuf A., Wibawanto A., Icksan AG., Syahrudin E., Juniarti. ES. Kanker Paru: Pedoman Diagnosis dan Penatalaksanaan di Indonesia. 2015; : 21–32.
- 31 Salsabila S, Intan SA, Fitriana DW. Gambaran Tipe Sel Kanker Paru Berdasarkan Usia, Jenis Kelamin, dan Paparan Rokok di RSUP Dr. M. Djamil Padang Tahun 2018-2020. *JIKESI* 2023; 4: 281–8.
- 32 Hulma MA, Basyar M, Mulyani H. Hubungan Karakteristik Penderita dengan Gambaran Sitopatologi pada Kasus Karsinoma Paru yang Dirawat di RSUP Dr. M. Djamil Padang. *JKA* 2014; 3: 196–201.
- 33 Haryati, Bakhriansyah M, Aisah SKN. Profil Penderita Kanker Paru Primer di Rumah Sakit Umum Daerah Ulin Banjarmasin Tahun 2006-2011. *J Resp IndJurnal Respi Indo* 2013; 33: 50–6.
- 34 Au PC, Lee AW, Lee VH, Wong IC, Hui RY, Cheung CL. The trends in lung cancer prevalence, incidence, and survival in Hong Kong over the past two decades (2002–2021): a population-based study. *Lancet Reg Heal West Pac* 2024; 45: 1–13.
- 35 Tamási L, Horváth K, Kiss Z, Bogos K, Ostoros G, Müller V *et al.* Age and Gender Specific Lung Cancer Incidence and Mortality in Hungary: Trends from 2011 Through 2016. *Pathol Oncol Res* 2021; 27: 1–9.
- 36 Omofoman BI B, H RB, Smith CJP, Sparks E, Bradley E, Bourke A *et al.* The distribution of lung cancer across sectors of society in the United Kingdom: A study using national primary care data. *BMC Public Health* 2011; 11: 1–9.
- 37 Ma Z, Zhu C, Wang H, Ji M, Huang Y, Wei X *et al.* Association between biological aging and lung cancer risk: Cohort study and Mendelian randomization analysis. *iScience* 2023; 26: 106018.

- 38 Ermayanti S., Afriani A., Nikmawati S., Russilawati., Medison I. SS. Perbedaan Gender dalam Pengaruhnya pada Karakteristik dan Prognostik Pasien Kanker Paru di Bagian Paru RSUP Dr. M. Djamil Padang. *JRI* 2021; 41: 245–50.
- 39 Sinaga FTY, Oktobiannobel J, Soemarwoto RAS, Yunanda V. Gambaran Progresivitas dan Prognosis Pada Pasien CA Paru di RSUD Dr. H. Abdul Moeloek Provinsi Lampung Tahun 2018-2021. *Medula* 2022; 12: 336–41.
- 40 Chairudin MR, Marhana IA, Erawati D. Profil Pasien Kanker Paru Primer yang Dirawat Inap dan Rawat Jalan di Rumah Sakit Umum Daerah Dr Soetomo Surabaya. *J Respirasi* 2020; 5: 65.
- 41 Jemal A, Society AC, Miller KD, Society AC, Society AC, Siegel RL *et al.* Higher Lung Cancer Incidence in Young Women Than Young Men in the United States. *N Engl J Med* 2020; 378: 1999–2009.
- 42 Chen W, Zhang S, Zou X. Evaluation on the incidence, mortality and tendency of lung cancer in China. *Thorac Cancer* 2010; 1: 35–40.
- 43 Ernawati Y, Ermayanti S, Herman D, Russilawati R. Faktor Risiko Kanker Paru pada Perempuan yang Dirawat di Bagian Paru RSUP Dr. M. Djamil Padang dan RSUD Solok: Penelitian Case Control. *JKA* 2019; 8: 1–7.
- 44 Megasari A, Bagiada M. Ketahanan hidup 1 tahun karsinoma paru di divisi Pulmonologi RSUP Sanglah Denpasar. *Medicina (B Aires)* 2020; 51: 1–5.
- 45 Zhu D, Ding R, Ma Y, Chen Z, Shi X, He P. Comorbidity in lung cancer patients and its association with hospital readmission and fatality in China. *BMC Cancer* 2021; 21: 1–11.
- 46 Grose D, Morrison DS, Devereux G, Jones R, Sharma D, Selby C *et al.* Comorbidities in lung cancer: Prevalence, severity and links with socioeconomic status and treatment. *Postgr Med J* 2014; 90: 305–10.
- 47 Dutkowska AE, Antczak A. Comorbidities in lung cancer. *Adv Respir Med* 2016; 84: 186–92.
- 48 Ananda RR, Ermayanti S, Abdiana A. Hubungan Staging Kanker Paru dengan Skala Nyeri pada Pasien Kanker Paru yang Dirawat di Bagian Paru RSUD DR M Djamil Padang. *JKA* 2018; 7: 430–4.
- 49 Pelosof L, Ahn C, Gao A, Horn L, Madrigales A, Cox J *et al.* Proportion of Never-Smoker Non-Small Cell Lung Cancer Patients at Three Diverse Institutions. *J Natl Cancer Inst* 2017; 109: 1–6.
- 50 Cufari ME, Proli C, De Sousa P, Raubenheimer H, Al Sahaf M, Chavan H *et al.* Increasing frequency of non-smoking lung cancer: Presentation of patients with early disease to a tertiary institution in the UK. *Eur J Cancer* 2017; 84: 55–9.
- 51 Walser T, Cui X, Yanagawa J, Lee JM, Heinrich E, Lee G *et al.* Smoking and lung cancer: The role of inflammation. *Proc Am Thorac Soc* 2008; 5: 811–5.

- 52 Meyers DE, Pasternak M, Dolter S, Grosjean HAI, Lim CA, Stukalin I *et al.* Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors. *JTO Clin Res Rep* 2023; 4: 3–8.
- 53 Dajczman E, Kasymjanova G, Kreisman H, Swinton N, Pepe C, Small D. Should patient-rated performance status affect treatment decisions in advanced lung cancer? *J Thorac Oncol* 2008; 3: 1133–6.
- 54 Supartono SA. Faktor-faktor yang Mempengaruhi Ketahanan Hidup Satu Tahun. *Med Hosp* 2012; 1: 25–31.
- 55 Azam F, Latif MF, Farooq A, Tirmazy SH, Alshahrani S, Bashir S *et al.* Performance Status Assessment by Using ECOG (Eastern Cooperative Oncology Group) Score for Cancer Patients by Oncology Healthcare Professionals. *Case Rep Oncol* 2019; 12: 728–36.
- 56 Sehgal K, Gill RR, Widick P, Bindal P, McDonald DC, Shea M *et al.* Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy. *JAMA Netw Open* 2021; 4: 1–9.
- 57 Zhang Y, Vaccarella S, Morgan E, Li M, Etcheberry J, Chokunonga E *et al.* Global variations in lung cancer incidence by histological subtype in 2020: a population-based study. *Lancet Oncol* 2023; 24: 1206–18.
- 58 ALQudah MA, ALFaqih MA, Hamouri S, Al-Shaikh AF, Haddad HK, Al-Quran WY *et al.* Epidemiology and histopathological classification of lung cancer: A study from Jordan, retrospective observational study. *Ann Med Surg* 2021; 65: 1–5.
- 59 Ridge C, McErlean A GM. Epidemiology of lung cancer. *Semin Interv Radiol* 2013; 30: 93–8.
- 60 Harris JE, Thun MJ, Mondul AM, Calle EE. Cigarette tar yields in relation to mortality from lung cancer in the cancer prevention study II prospective cohort, 1982-8. *Br Med J* 2004; 328: 72–6.
- 61 Alfarisa S, Mitra E, Wahyuni S. Karakteristik Pasien Kanker Paru di RSUP Dr. M. Djamil Padang Tahun 2021. *Sci J* 2023; 2: 141–9.
- 62 Flores R, Patel P, Alpert N, Pyenson B, Taioli E. Association of Stage Shift and Population Mortality among Patients with Non-Small Cell Lung Cancer. *JAMA Netw Open* 2021; 4: 1–11.
- 63 Emmerick ICM, Singh A, Powers M, Lou F, Lin P, Maxfield M *et al.* Factors associated with diagnosis of stages I and II lung cancer: a multivariate analysis. *Rev Saude Publica* 2021; 55: 1–10.
- 64 Jayanti E, Hakim AR IP. *Evaluasi penggunaan kemoterapi pada pasien kanker paru di instalasi rawat inap rs "x"*. 2013.
- 65 Rusdi NK, Sari EN, Wulandari N. Ketepatan Obat, Dosis, dan Potensi Interaksi Obat pada Pasien Kanker Paru di Rumah Sakit X Jawa Barat

Periode 2019-2021. *JSK* 2023; 5: 313–23.

- 66 Rajeswaran A, Trojan A, Burnand B, Giannelli M. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: A systematic review of randomi. *Lung Cancer* 2008; 59: 1–11.
- 67 Usman I, Sabrina Ermayanti, Afriani Afriani. Profile of Side Effects of Chemotherapy in Non-Small Cell Lung Cancer Patients (NSCLC) Undergoing Chemotherapy at Dr. M. Djamil General Hospital, Padang, Indonesia. *BSM* 2022; 6: 2826–34.
- 68 Syahrudin E, Hudoyo A, Jusuf A, Pulmonologi D, Ilmu D, Respirasi K. Respons Dan Toleransi Pasien Adenokarsinoma Paru Stage III Dan IV Untuk Pemberian Kemoterapi Dengan Rejimen Paclitaxel (Paxus®) Plus Carboplatin. *J Respir Indo* 2010; 30: 105–11.
- 69 Syahrudin E, Marlina N, Hudoyo A, Persahabatan S. Efikasi dan Toksisitas Rejimen Sisplatin + Etoposid untuk Kemoterapi Kanker Paru Jenis Karsinoma Bukan Sel Kecil (KPKBSK) Stage Lanjut Efficacy and Toxicity Chemotherapy With Cisplatin + Etoposide Regiment in Advanced Stage non-Small Cell Lung Cancer. *J Respir Indo* 2012; 32: 25–35.
- 70 M SG, Mohapatra PR, Bhuniya S, Das Majumdar SK, Mishra P, Panigrahi MK *et al.* Impact of Comorbidity Scores on the Overall Survival of Patients With Advanced Non-small Cell Lung Cancer: A Real-World Experience From Eastern India. *Cureus* 2022; 14: 1–10.
- 71 Joode K De, Dumoulin DW, Engelen V, Bloemendal HJ. Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients' perspective. *Eur J Cancer* 2020; 136.
- 72 Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. *JNCCN* 2009; 7: 99–108.
- 73 Peppone LJ, Mustian KM, Morrow GR, Dozier AM, Ossip DJ, Janelins MC *et al.* The Effect of Cigarette Smoking on Cancer Treatment–Related Side Effects. *Oncol* 2011; 16: 1784–92.
- 74 Hennessy MA, Linehan A, Cowzer D, Coyne ZL, Fitzpatrick O, Barrett F *et al.* Chemotherapy in the Covid-19 era : the patient ' s perception. *Ir J Med Sci* 2021; 190: 1303–8.
- 75 Magno S, Linardos M, Carnevale S, Dilucca M, Di Leone A, Terribile DA *et al.* The impact of the COVID-19 pandemic on breast cancer patients awaiting surgery: Observational survey in an Italian University hospital. *Breast J* 2020; 26: 1597–602.
- 76 Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. *J Clin Oncol* 2004; 22: 3852–9.

- 77 Nurwidya F. Peran Stem Sel Kanker pada Kegagalan Kemoterapi. *J respir Indo* 2015; 35: 57–60.
- 78 Dechow T, Riera-Knorrenschild J, Hackanson B, Janssen J, Schulz H, Chiabudini M *et al*. First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Results of the NEPTUN study. *Cancer Med* 2021; 10: 8127–37.
- 79 Boonsong T, Usaha S, Nakwan N, Ruklerd T, Khongthong P, Chang A. Survival Analysis and Clinical Outcomes between Paclitaxel and Carboplatin Versus Carboplatin and Gemcitabine in Patients with Advanced-stage Non-small-cell Lung Cancer: A Single-center Cohort Study. *Asian Pac J Cancer Prev* 2022; 23: 3371–8.
- 80 Cherif H, Bacha S, Habibech S, Racil H, Cheikhrouhou S, Chaouech N *et al*. Chemotherapy toxicity in advanced non-small cell lung cancer and its impact on survival. *Eur Respir J* 2016; 48: 1–10.
- 81 Erlain TM, Burke A BC. Life after Cell Death-Survival and Survivorship Following Chemotherapy. *Cancer* 2021; 13: 1–17.

